P2Y receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database by M.P. Abbracchio et al.
IUPHAR/BPS Guide to Pharmacology CITE
https://doi.org/10.2218/gtopdb/F52/2019.4
P2Y receptors (version 2019.4) in the IUPHAR/BPS Guide to
Pharmacology Database
Maria-Pia Abbracchio1, Jean-Marie Boeynaems2, José L. Boyer3, Geoffrey Burnstock4, Stefania Ceruti1, Marta
Fumagalli1, Christian Gachet5, Rebecca Hills6, Robert G. Humphries7, Kazu Inoue8, Kenneth A. Jacobson9,
Charles Kennedy10, Brian F. King4, Davide Lecca1, Christa E. Müller11, Maria Teresa Miras-Portugal12, Vera
Ralevic13 and Gary A. Weisman14
1. University of Milan, Italy
2. Université Libre de Bruxelles, Belgium
3. University of North Carolina, USA
4. Royal Free Hospital School of Medicine, UK
5. INSERM, France
6. University of Edinburgh, UK
7. AstraZeneca, UK
8. University of Kyushu, Japan
9. National Institutes of Health, USA
10. University of Strathclyde, UK
11. Universität Bonn, Germany
12. Universidad Complutense de Madrid, Spain
13. University of Nottingham, UK
14. University of Missouri, USA
Abstract
P2Y receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on P2Y Receptors [3, 5]) are
activated by the endogenous ligands ATP, ADP, uridine triphosphate, uridine diphosphate and UDP-glucose.
The relationship of many of the cloned receptors to endogenously expressed receptors is not yet established
and so it might be appropriate to use wording such as 'uridine triphosphate-preferring (or ATP-, etc.) P2Y
receptor' or 'P2Y1-like', etc., until further, as yet undefined, corroborative criteria can be applied [46, 109, 187,
375, 388].
Clinically used drugs acting on these receptors include the dinucleoside polyphosphate diquafosol, agonist of the
P2Y2 receptor subtype, approved in Japan for the management of dry eye disease [236], and the P2Y12
receptor antagonists prasugrel, ticagrelor and cangrelor, all approved as antiplatelet drugs [52, 316].
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This is a citation summary for P2Y receptors in the Guide to Pharmacology database (GtoPdb). It exists purely
as an adjunct to the database to facilitate the recognition of citations to and from the database by citation
analyzers. Readers will almost certainly want to visit the relevant sections of the database which are given here
under database links.
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GtoPdb is an expert-driven guide to pharmacological targets and the substances that act on them. GtoPdb is a
reference work which is most usefully represented as an on-line database. As in any publication this work
should be appropriately cited, and the papers it cites should also be recognized. This document provides a
citation for the relevant parts of the database, and also provides a reference list for the research cited by those
parts.
Please note that the database version for the citations given in GtoPdb are to the most recent preceding version
in which the family or its subfamilies and targets were substantially changed. The links below are to the current
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